Bio-Techne Corporation (TECH) EPS Estimated At $0.85

January 22, 2018 - By Jan Rainey

 Bio Techne Corporation (TECH) EPS Estimated At $0.85
Investors sentiment decreased to 1.21 in Q3 2017. Its down 0.23, from 1.44 in 2017Q2. It dropped, as 16 investors sold Bio-Techne Corporation shares while 86 reduced holdings. 36 funds opened positions while 87 raised stakes. 35.91 million shares or 2.04% less from 36.66 million shares in 2017Q2 were reported.
7,521 were accumulated by State Of Wisconsin Inv Board. Deutsche Bancshares Ag owns 78,423 shares or 0.01% of their US portfolio. Hutchin Hill Cap Limited Partnership holds 0.04% or 8,500 shares. Envestnet Asset Mngmt Inc stated it has 9,665 shares. Ameriprise Fincl Inc has 201,486 shares for 0.01% of their portfolio. Citigroup reported 0% stake. 2,029 were reported by Huntington Bancorp. Manufacturers Life Ins Communications The reported 81,235 shares. Contravisory reported 24 shares. Panagora Asset Mgmt Inc invested in 2,868 shares. Moreover, Peak6 Invs Lp has 0% invested in Bio-Techne Corporation (NASDAQ:TECH). Eaton Vance Mgmt reported 2,566 shares stake. Price T Rowe Assocs Md invested in 0% or 16,446 shares. Mondrian Invest Partners holds 0.12% or 37,544 shares. Underhill Limited Liability Company reported 1,900 shares stake.

Since August 10, 2017, it had 0 insider purchases, and 4 insider sales for $164,629 activity. Shares for $128,909 were sold by HOLBROOK KAREN A on Wednesday, September 6.

Analysts expect Bio-Techne Corporation (NASDAQ:TECH) to report $0.85 EPS on February, 6.They anticipate $0.11 EPS change or 14.86 % from last quarter’s $0.74 EPS. TECH’s profit would be $31.84 million giving it 41.39 P/E if the $0.85 EPS is correct. After having $0.82 EPS previously, Bio-Techne Corporation’s analysts see 3.66 % EPS growth. The stock increased 0.50% or $0.7 during the last trading session, reaching $140.72. About 193,657 shares traded or 18.70% up from the average. Bio-Techne Corporation (NASDAQ:TECH) has risen 6.75% since January 22, 2017 and is uptrending. It has underperformed by 9.95% the S&P500.

Bio-Techne Corporation (NASDAQ:TECH) Ratings Coverage

Among 9 analysts covering BIO-TECHNE Corp (NASDAQ:TECH), 5 have Buy rating, 0 Sell and 4 Hold. Therefore 56% are positive. BIO-TECHNE Corp had 19 analyst reports since August 18, 2015 according to SRatingsIntel. The company was maintained on Tuesday, December 5 by Leerink Swann. Zacks upgraded Bio-Techne Corporation (NASDAQ:TECH) on Tuesday, September 22 to “Hold” rating. Robert W. Baird maintained Bio-Techne Corporation (NASDAQ:TECH) on Tuesday, October 31 with “Buy” rating. The rating was upgraded by Zacks on Tuesday, September 1 to “Sell”. The firm earned “Buy” rating on Monday, October 23 by Robert W. Baird. The rating was reinitiated by Leerink Swann with “Outperform” on Thursday, November 10. On Thursday, October 29 the stock rating was downgraded by Stephens to “Equal-Weight”. The rating was initiated by Citigroup with “Buy” on Thursday, February 9. The rating was upgraded by Zacks on Tuesday, August 18 to “Sell”. The firm earned “Hold” rating on Thursday, July 13 by Wells Fargo.

Bio-Techne Corporation, together with its subsidiaries, develops, makes, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. The company has market cap of $5.27 billion. It operates through three divisions: Biotechnology, Protein Platforms, and Diagnostics. It has a 72.16 P/E ratio. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets.

More notable recent Bio-Techne Corporation (NASDAQ:TECH) news were published by: Nasdaq.com which released: “Bio-Techne Corp (TECH) Ex-Dividend Date Scheduled for November 09, 2017” on November 08, 2017, also Prnewswire.com with their article: “Bio-Techne Acquires Atlanta Biologicals Inc.” published on January 02, 2018, Seekingalpha.com published: “Bio-Techne (TECH) Q4 2017 Results – Earnings Call Transcript” on August 08, 2017. More interesting news about Bio-Techne Corporation (NASDAQ:TECH) were released by: Seekingalpha.com and their article: “Bio-Techne (TECH) Q1 2018 Results – Earnings Call Transcript” published on October 31, 2017 as well as Seekingalpha.com‘s news article titled: “Bio-Techne Acquires Trevigen In All Cash Deal” with publication date: September 07, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: